

# Pierre Cordelier

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8184807/pierre-cordelier-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98  
papers

3,726  
citations

33  
h-index

59  
g-index

111  
ext. papers

4,317  
ext. citations

6.5  
avg, IF

5.34  
L-index

#	Paper	IF	Citations
98	The antitumoral activity of TLR7 ligands is corrupted by the microenvironment of pancreatic tumors.. <i>Molecular Therapy</i> , <b>2022</b> ,	11.7	1
97	Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 568-582	12.5	9
96	micro-RNA 21 detection with a limit of 2 pM in 1´min using a size-accordable concentration module operated by electrohydrodynamic actuation. <i>Biosensors and Bioelectronics</i> , <b>2021</b> , 178, 112992	11.8	1
95	Pancreatic cancer intrinsic PI3K activity accelerates metastasis and rewires macrophage component. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e13502	12	3
94	A Novel Imaging Approach for Single-Cell Real-Time Analysis of Oncolytic Virus Replication and Efficacy in Cancer Cells. <i>Human Gene Therapy</i> , <b>2021</b> , 32, 166-177	4.8	3
93	The E3 ubiquitin ligase TRIP12 participates in cell cycle progression and chromosome stability. <i>Scientific Reports</i> , <b>2020</b> , 10, 789	4.9	9
92	Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 153-168	24.2	155
91	The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?. <i>Molecular Therapy</i> , <b>2020</b> , 28, 357-366	11.7	19
90	One Two Punch: Combination Chemotherapy Knocks Out Pancreatic Cancer. <i>Molecular Therapy</i> , <b>2020</b> , 28, 1751-1752	11.7	
89	Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer. <i>Molecular Therapy - Nucleic Acids</i> , <b>2019</b> , 17, 491-503	10.7	25
88	Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	30
87	Technological Challenges and Future Issues for the Detection of Circulating MicroRNAs in Patients With Cancer. <i>Frontiers in Chemistry</i> , <b>2019</b> , 7, 815	5	14
86	Spatial Analysis of Nanofluidic-Embedded Biosensors for Wash-Free Single-Nucleotide Difference Discrimination. <i>ACS Sensors</i> , <b>2018</b> , 3, 606-611	9.2	11
85	Keep Quiet and Stay in Line! Smart Polymers to Keep an Eye on Pancreatic Tumors. <i>Molecular Therapy</i> , <b>2018</b> , 26, 940-941	11.7	1
84	Microfluidics for minute DNA sample analysis: open challenges for genetic testing of cell-free circulating DNA in blood plasma. <i>Micro and Nano Engineering</i> , <b>2018</b> , 1, 25-32	3.4	6
83	Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 42916	4.9	79
82	CRISPR/Cas9: Transcending the Reality of Genome Editing. <i>Molecular Therapy - Nucleic Acids</i> , <b>2017</b> , 7, 211-222	10.7	63

81	Proper sister chromatid disjunction requires CDA and PARP-1. <i>Cell Cycle</i> , <b>2017</b> , 16, 1239-1240	4.7	
80	Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	25
79	Regulating the expression of therapeutic transgenes by controlled intake of dietary essential amino acids. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 746-51	44.5	9
78	REG3 $\beta$ Plays a Key Role in IL17RA Protumoral Effect-Response. <i>Cancer Research</i> , <b>2016</b> , 76, 2051	10.1	3
77	Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. <i>Human Gene Therapy</i> , <b>2016</b> , 27, 184-92	4.8	6
76	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. <i>European Journal of Cancer</i> , <b>2016</b> , 54, 75-83	7.5	107
75	The Promise of Gene Therapy for Pancreatic Cancer. <i>Human Gene Therapy</i> , <b>2016</b> , 27, 127-33	4.8	13
74	Endoscopic ultrasound-guided fine-needle aspiration plus KRAS and GNAS mutation in malignant intraductal papillary mucinous neoplasm of the pancreas. <i>Endoscopy International Open</i> , <b>2016</b> , 4, E1228-E1235	3	18
73	KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , <b>2016</b> , 7, e157	4.2	94
72	Hopes, Promises, and Future Directions of Gene and Cell Therapies in France. <i>Human Gene Therapy</i> , <b>2016</b> , 27, 96-7	4.8	1
71	Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 50-6	3	46
70	IL17 Functions through the Novel REG3 $\beta$ JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 4852-62	10.1	68
69	Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1590-8	8.7	13
68	Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. <i>Human Gene Therapy</i> , <b>2015</b> , 26, 104-13	4.8	21
67	Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. <i>EMBO Molecular Medicine</i> , <b>2015</b> , 7, 735-53	12	131
66	First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. <i>Molecular Therapy</i> , <b>2015</b> , 23, 779-89	11.7	73
65	Salivary MicroRNA in Pancreatic Cancer Patients. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130996	3.7	77
64	Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 10758-68	5.6	28

63	The E3 ubiquitin ligase thyroid hormone receptor-interacting protein 12 targets pancreas transcription factor 1a for proteasomal degradation. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 35593-604	5.4	13
62	Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. <i>PLoS ONE</i> , <b>2014</b> , 9, e103159	3.7	86
61	MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 11199-209	5.6	37
60	Modulating MicroRNA Expression for the Therapy of Pancreatic Cancer <b>2014</b> , 189-197		
59	miRNA in clinical practice: pancreatic cancer. <i>Clinical Biochemistry</i> , <b>2013</b> , 46, 933-6	3.5	30
58	The Role of the 3' Untranslated Region in the Post-Transcriptional Regulation of KLF6 Gene Expression in Hepatocellular Carcinoma. <i>Cancers</i> , <b>2013</b> , 6, 28-41	6.6	4
57	Targeting miR-21 for the therapy of pancreatic cancer. <i>Molecular Therapy</i> , <b>2013</b> , 21, 986-94	11.7	164
56	DNA methylation and cancer diagnosis. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 15029-58	6.3	113
55	MicroRNA analysis: is it ready for prime time?. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 343-7	5.5	8
54	KRAS mutations and their correlation with survival of patients with advanced pancreatic cancer. <i>Pancreas</i> , <b>2013</b> , 42, 543-4	2.6	11
53	The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. <i>PLoS ONE</i> , <b>2013</b> , 8, e55513	3.7	21
52	Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. <i>Pancreatology</i> , <b>2012</b> , 12, 27-34	3.8	45
51	Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. <i>BMC Cancer</i> , <b>2012</b> , 12, 15	4.8	96
50	Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. <i>Cancer Research</i> , <b>2012</b> , 72, 1395-406	10.1	77
49	Tie1 deficiency induces endothelial-mesenchymal transition. <i>EMBO Reports</i> , <b>2012</b> , 13, 431-9	6.5	36
48	Le cancer du pancréas. <i>Bulletin De L'Academie Nationale De Medecine</i> , <b>2012</b> , 196, 1819-1828	0.1	
47	Genetic and epigenetic alterations in pancreatic carcinogenesis. <i>Current Genomics</i> , <b>2011</b> , 12, 15-24	2.6	82
46	Molecular endoscopic ultrasound for diagnosis of pancreatic cancer. <i>Cancers</i> , <b>2011</b> , 3, 872-82	6.6	5

45	Regulation of membrane cholecystokinin-2 receptor by agonists enables classification of partial agonists as biased agonists. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 6707-19	5.4	14
44	MicroRNAs in Pancreatic Cancer: Potential Interests as Biomarkers and Therapeutic Tools <b>2011</b> , 287-307		1
43	Using lentiviral vectors for efficient pancreatic cancer gene therapy. <i>Cancer Gene Therapy</i> , <b>2010</b> , 17, 315-24	3.4	25
42	R115: Ciblage des microARNs oncogéniques pour la thérapie du cancer pancréatique. <i>Bulletin Du Cancer</i> , <b>2010</b> , 97, S60	2.4	
41	R89 - Oral: L'expertise toxicologique d'un nouvel agent thérapeutique anticancéreux issu de la biotechnologie en vue de sa première administration chez l'homme. <i>Bulletin Du Cancer</i> , <b>2010</b> , 97, S51	2.4	
40	MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 603-12	5.5	178
39	The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 1107-18	5.5	128
38	The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 880-8	13.4	28
37	Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. <i>PLoS ONE</i> , <b>2009</b> , 4, e6278	3.7	169
36	let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. <i>Human Gene Therapy</i> , <b>2009</b> , 20, 831-44	4.8	128
35	Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. <i>Endoscopy</i> , <b>2009</b> , 41, 552-7	3.4	73
34	Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. <i>Current Genomics</i> , <b>2009</b> , 10, 353-60	2.6	62
33	Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. <i>Endocrinology</i> , <b>2008</b> , 149, 3137-47	4.8	26
32	Expression of the transcription factor Klf6 in cirrhosis, macronodules, and hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 78-86	4	16
31	KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. <i>Cell Death and Differentiation</i> , <b>2007</b> , 14, 1202-10	12.7	47
30	Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. <i>Cancer Gene Therapy</i> , <b>2007</b> , 14, 19-29	5.4	14
29	Enjoy the Silence: The Story of let-7 MicroRNA and Cancer. <i>Current Genomics</i> , <b>2007</b> , 8, 229-33	2.6	72
28	Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity. <i>Gut</i> , <b>2007</b> , 56, 107-14	19.2	15

27	Potential of recombinant SV40-based vectors for gene therapy. <i>Recent Patents on DNA &amp; Gene Sequences</i> , <b>2007</b> , 1, 93-9		2
26	Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 19156-71	5.4	19
25	Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. <i>Molecular Therapy</i> , <b>2006</b> , 14, 758-67	11.7	33
24	Using gene delivery to protect HIV-susceptible CNS cells: inhibiting HIV replication in microglia. <i>Virus Research</i> , <b>2006</b> , 118, 87-97	6.4	13
23	Long-term gene expression in dividing and nondividing cells using SV40-derived vectors. <i>Molecular Biotechnology</i> , <b>2006</b> , 34, 257-70	3	9
22	What they are, how they work and why they do what they do? The story of SV40-derived gene therapy vectors and what they have to offer. <i>Current Gene Therapy</i> , <b>2005</b> , 5, 151-65	4.3	19
21	Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. <i>Human Gene Therapy</i> , <b>2005</b> , 16, 1175-93	4.8	31
20	Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells. <i>Human Gene Therapy</i> , <b>2005</b> , 050921065448001	4.8	
19	Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. <i>Gene Therapy</i> , <b>2004</b> , 11, 1627-37	4	32
18	Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV. <i>Molecular Therapy</i> , <b>2003</b> , 7, 801-10	11.7	34
17	Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. <i>Oligonucleotides</i> , <b>2003</b> , 13, 281-94		43
16	Inhibition of HIV-1 in the central nervous system by IFN-alpha2 delivered by an SV40 vector. <i>Journal of Interferon and Cytokine Research</i> , <b>2003</b> , 23, 477-88	3.5	16
15	Using new gene delivery systems to advance HIV gene therapy. <i>Clinical and Applied Immunology Reviews</i> , <b>2003</b> , 3, 247-259		2
14	HIV-1 proprotein processing as a target for gene therapy. <i>Gene Therapy</i> , <b>2003</b> , 10, 467-77	4	22
13	Conditional expression of alpha1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV. <i>Gene Therapy</i> , <b>2003</b> , 10, 2153-6	4	10
12	Virus-based vectors for gene expression in mammalian cells: SV40. <i>New Comprehensive Biochemistry</i> , <b>2003</b> , 38, 71-91		1
11	Mechanisms of alpha1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2003</b> , 1638, 197-207	6.9	14
10	Conditional expression of IFN-alpha and IFN-gamma activated by HBV as genetic therapy for hepatitis B. <i>Journal of Interferon and Cytokine Research</i> , <b>2003</b> , 23, 709-21	3.5	5

9	Trans-activated interferon-alpha2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>2002</b> , 11, 817-28		11
8	Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 1425-30	7	23
7	SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters. <i>Gene Therapy</i> , <b>2001</b> , 8, 1033-42	4	18
6	Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling. <i>FASEB Journal</i> , <b>2001</b> , 15, 2300-2	0.9	36
5	Signal transduction of somatostatin receptors negatively controlling cell proliferation. <i>Journal of Physiology (Paris)</i> , <b>2000</b> , 94, 205-10		79
4	Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 9180-5	11.5	96
3	The activation of neuronal NO synthase is mediated by G-protein betagamma subunit and the tyrosine phosphatase SHP-2. <i>FASEB Journal</i> , <b>1999</b> , 13, 2037-50	0.9	27
2	Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 9343-8	11.5	123
1	Current Understanding of microRNAs as Therapeutic Targets in Cancer 167-172		1